Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis

被引:66
|
作者
Nead, Kevin T. [1 ]
Sinha, Sumi [2 ,3 ]
Yang, David D. [2 ,3 ]
Nguyen, Paul L. [2 ,3 ]
机构
[1] Univ Penn, Perelman Ctr Adv Med, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
关键词
Androgen deprivation therapy; Depression; Prostate cancer; Behavioral symptoms; Hormone therapy; QUALITY-OF-LIFE; MEN; ANXIETY; INTERMITTENT; IMPACT; SYMPTOMATOLOGY; SUPPRESSION; MORTALITY; SURVIVORS; SYMPTOMS;
D O I
10.1016/j.urolonc.2017.07.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is increasing evidence that androgen deprivation therapy (ADT) may be associated with depression. Existing studies have shown conflicting results. Methods: PubMed, Web of Science, Embase, and PsycINFO were queried on April 5, 2017. Eligible studies were in English and reported depression among individuals with prostate cancer exposed to a course of ADT vs. a lesser-exposed group (e.g., any-ADT vs. no ADT and continuous ADT vs. intermittent ADT). We used the MOOSE statement guidelines and the Cochrane Review Group's data extraction template. Study quality was evaluated by Newcastle-Ottawa Scale criteria. We conducted a random-effects meta-analysis to calculate summary statistic risk ratios (RRs) and 95% CIs. Heterogeneity was quantified using the I-2 statistic and prespecified subgroup analysis. Small study effects were evaluated using Begg and Egger statistics. Results: A total of 1,128 studies were initially identified and evaluated. A meta-analysis of 18 studies among 168,756 individuals found that ADT use conferred a 41% increased risk of depression (RR = 1.41; 95% CI: 1.18-1.70; P < 0.001). We found a consistent strong statistically significant association when limiting our analysis to studies in localized disease (RR = 1.85; 95% CI: 1.20-2.85; P = 0.005) and those using a clinical diagnosis of depression (RR = 1.19; 95% CI: 1.08-1.32; P = 0.001). We did not find an association for continuous ADT with depression risk compared to intermittent ADT (RR = 1.00; 95% CI: 0.50-1.99; P = 0.992). There was no statistically significant evidence of small study effects. Statistically significant heterogeneity in the full analysis (I-2 = 80%; 95% CI: 69-87; P < 0.001) resolved when examining studies using a clinical diagnosis of depression (I-2 = 16%; 95% CI: 0-60; P = 0.310). Conclusion: The currently available evidence suggests that ADT in the treatment of prostate cancer is associated with an increased risk of depression. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:664.e1 / 664.e9
页数:9
相关论文
共 50 条
  • [1] Association of Androgen Deprivation Therapy in the Treatment of Prostate Cancer and Depression: A Systematic Review and Meta-analysis
    Nead, K. T.
    Yang, D. D.
    Sinha, S.
    Nguyen, P. L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E257 - E257
  • [2] Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis
    Zhenlang Guo
    Yiyu Huang
    Leiliang Gong
    Shu Gan
    Franky Leung Chan
    Chiming Gu
    Songtao Xiang
    Shusheng Wang
    [J]. Prostate Cancer and Prostatic Diseases, 2018, 21 : 451 - 460
  • [3] Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis
    Guo, Zhenlang
    Huang, Yiyu
    Gong, Leiliang
    Gan, Shu
    Chan, Franky Leung
    Gu, Chiming
    Xiang, Songtao
    Wang, Shusheng
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 451 - 460
  • [4] Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
    Nead, K. T.
    Sinha, S.
    Nguyen, P. L.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) : 259 - 264
  • [5] Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review
    Meng, Fanzheng
    Zhu, Shimiao
    Zhao, Jinsheng
    Vados, Larissa
    Wang, Lei
    Zhao, Yusheng
    Zhao, Dan
    Niu, Yuanjie
    [J]. BMC CANCER, 2016, 16
  • [6] Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review
    Fanzheng Meng
    Shimiao Zhu
    Jinsheng Zhao
    Larissa Vados
    Lei Wang
    Yusheng Zhao
    Dan Zhao
    Yuanjie Niu
    [J]. BMC Cancer, 16
  • [7] Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
    Hinojosa-Gonzalez, David E.
    Zafar, Affan
    Saffati, Gal
    Kronstedt, Shane
    Zlatev, Dimitar V.
    Khera, Mohit
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (03) : 507 - 519
  • [8] Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
    K T Nead
    S Sinha
    P L Nguyen
    [J]. Prostate Cancer and Prostatic Diseases, 2017, 20 : 259 - 264
  • [9] Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
    Serpa Neto, A.
    Tobias-Machado, M.
    Esteves, M. A. P.
    Senra, M. D.
    Wroclawski, M. L.
    Fonseca, F. L. A.
    dos Reis, R. B.
    Pompeo, A. C. L.
    Giglio, A. D.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) : 36 - 44
  • [10] Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis
    Wroclawski, M. L.
    Serpa Neto, A.
    Tobias-Machado, M.
    Esteves, M. A.
    Fonseca, F. L.
    Senra, M. D.
    Pompeo, A. C.
    Del Giglio, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)